Physician profile
Aaron Michael Goodman
NPI 1851603559
$134,087.60
in general payments reported to CMS, 2019-2025
13 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $17K · 2021: $23K · 2022: $6,319 · 2023: $14.27 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $12K · Honoraria: $2,740 · Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,750.00 |
| Travel and Lodging | $12,262.87 |
| Honoraria | $2,740.00 |
| Food and Beverage | $1,288.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $51,236.30 | 2019-2022 | |
| Pfizer INC. | $42,128.54 | 2025 | |
| Eusa Pharma (US) LLC | $19,069.44 | 2019-2021 | |
| Genentech, INC. | $9,994.35 | 2019 | |
| Kyowa Kirin, INC. | $6,333.98 | 2019 | |
| Rigel Pharmaceuticals, INC. | $3,847.53 | 2025 | Rezlidhia |
| Daiichi Sankyo INC. | $1,302.77 | 2019 | |
| Karyopharm Therapeutics INC. | $97.69 | 2021 | |
| Medexus Pharma, INC. | $51.23 | 2025 | Grafapex |
| Genmab U.S., INC. | $14.27 | 2023 | Epkinly |
| Epizyme, INC. | $11.50 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.